Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 9/20 | 0.56 |
| ▸ | ESR2 | Q92731 | 7/20 | 0.56 |
| ▸ | VDR | P11473 | 8/20 | 0.48 |
| ▸ | AR | P10275 | 6/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2949204 | 0.86 | ESR1 (0.56) | ESR1ESR2VDRARHDAC6 | |
| SCHEMBL2945689 | 0.84 | VDR (0.44) | ESR1ESR2VDRARHDAC6 | |
| SCHEMBL2950878 | 0.84 | ESR1 (0.49) | ESR1ESR2VDRARHDAC6 | |
| SCHEMBL2943706 | 0.79 | VDR (0.81) | VDRARHDAC6HDAC3 | |
| SCHEMBL13236437 | 0.79 | VDR (0.40) | VDRARHDAC6HDAC3 | |
| SCHEMBL2941251 | 0.79 | VDR (0.67) | VDRARHDAC6HDAC3 | |
| SCHEMBL2947658 | 0.79 | ESR1 (0.56) | ESR1ESR2VDRAR | |
| SCHEMBL13236433 | 0.78 | VDR (0.69) | VDRARHDAC6HDAC3 | |
| SCHEMBL2942499 | 0.78 | VDR (0.69) | VDRARHDAC6HDAC3 | |
| SCHEMBL13236423 | 0.78 | VDR (0.69) | VDRARHDAC6HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7750184-B2 | Vitamin D receptor modulators | ELI LILLY AND COMPANY (US) | 2010-07-06 | — | — | US | disclosed |
| US-7750184-B2 | Vitamin D receptor modulators | ELI LILLY AND COMPANY (US) | 2010-07-06 | — | — | US | disclosed |
| US-7750184-B2 | Vitamin D receptor modulators | ELI LILLY AND COMPANY (US) | 2010-07-06 | — | — | US | disclosed |
| US-20060293385-A1 | Vitamin d receptor modulators | ELI LILLY AND COMPANY, AN INDIANA CORPORATION | 2006-12-28 | — | — | US | disclosed |
| EP-1687265-A2 | VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005051898-A2 | VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293385-A1 | Vitamin d receptor modulators | VDR, CYP24A1, CYP2R1 | ESR1 186/4885ESR2 163/4885VDR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.